Device Firms Look To 513(g) For User Fee Answers; FDA Developing Guidance
An FDA guidance document clarifying "opinions" offered to device makers under section 513(g) of the FD&C Act is targeted for implementation by Dec. 31, according to the agency
More from Archive
More from Medtech Insight
A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.
CMS is proposing to classify all CGMs and insulin pumps as “items requiring frequent and substantial servicing” to expand device choice and access for Medicare beneficiaries. Under this framework, CMS also intends to move Class II devices, which include CGMs from Abbott and Dexcom and pumps from Tan
An upcoming US FDA advisory panel meeting will discuss adding a new indication to allow dermal fillers to be used in the upper chest, or décolletage. Plastic surgeons expect this could drive interest in the procedure, which is already performed off-label.